Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Algernon Pharmaceuticals: Ready 2 Run Away From The Pack >>>

KEY AREAS OF FOCUS

CLINICAL EXPERTISE IN UNDERSTANDING AND DELIVERING VALUE

Inflammatory Bowel Disease

The Global Inflammatory Bowel
Diseases (IBD) Drug Market is
Estimated At $8.5B In 2016
and $9.5B In 2020

• An Orphan Disease

• Competition Moderate

• Phase II Trial – 17 Patients, Open
Label, 6 Weeks Estimated Cost
$750,000 (Innovation Pharma)

https://nashpharmaceuticals.com/wp-content/uploads/2018/08/Nash-Pharmaceuticals-July-Deck-2018.pdf

Begin Phase IIA Study
Nash Pharma plans to begin a Phase IIA study for its leading drug candidate in IBD.

https://breathtecbiomedical.com/2018/09/13/breathtec-provides-nash-pharmaceuticals-plans-for-next-year/

“We are very pleased to be presenting the data from our IBD research program at the upcoming Digestive Disease Week Conference”, said Christopher J. Moreau, CEO of Nash Pharmaceuticals. “It will be the first time that the Company will have an opportunity to present its findings to the global IBD research community.”

https://breathtecbiomedical.com/2019/02/13/nash-pharmaceuticals-to-present-data-on-its-inflammatory-bowel-disease-research-program-at-the-digestive-disease-week-annual-conference/

Did you notice the Phase IIA Trial in IBD is only 6 Weeks in duration?

From Zero to ($)9.58



/////AMG